association of alpha-1 antitrypsin level and lung function in patients with chronic obstructive pulmonary disease

Clicks: 229
ID: 146133
2017
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Introduction/Objective. Alpha-1 antitrypsin deficiency is a well established inherited risk factor for chronic obstructive pulmonary disease (COPD); however, alpha-1 antitrypsin level may result in different lung function reduction. The aim of our study was to evaluate possible associations of alpha-1 antitrypsin level and lung function in COPD patients with different alpha-1 antitrypsin phenotypes. Methods. Serum alpha-1 antitrypsin concentration from patients (n = 1,167) with COPD, defined according to the GOLD criteria, were analyzed by nephelometry, and alpha-1 antitrypsin phenotype was determined by means of isoelectric-focusing. Results. In COPD patients without alpha-1 antitrypsin deficiency (MM), a significant negative association of lung function (FEV1) with serum alpha-1 antitrypsin (r = -0.511; p < 0.05) and C-reactive protein (CRP) concentrations (r = -0.583; p < 0.05) was detected; moreover, the level of alpha-1 antitrypsin positively correlated with CRP concentration (r = 0.667; p < 0.05). Conclusions. In patients without alpha-1 antitrypsin deficiency, detected negative association of alpha-1 antitrypsin level with FEV1 and positive association with the CRP level defined the importance of alpha-1 antitrypsin for lung function in COPD patients.
Reference Key
danielius2017srpskiassociation Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;Serapinas Danielius;Nutautiene Ruta;Pukinskaite Ruta;Bartkeviciene Daiva;Barkauskiene Diana;Sakalauskas Raimundas
Journal Journal of Asian natural products research
Year 2017
DOI
10.2298/SARH160809148S
URL
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.